8
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T1992 | Mertansine | DM1,Maytansinoid DM1 | Microtubule Associated |
Mertansine (DM1) refers to the thiol-containing maytansinoid, DM1 (N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) attached to a monoclonal antibody through reaction of the thiol group with the SPP (N-succinimidyl 4... | |||
T76939 | Cantuzumab mertansine | ||
Cantuzumab mertansine (SB-408075; huC242-DM1), an antibody-drug conjugate (ADC), comprises the potent maytansine derivative (DM1) linked to the humanized monoclonal antibody (huC242) targeting CanAg. Demonstrating cytoto... | |||
T77406 | Lorvotuzumab | Others | |
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds to CD56 (NCAM1). Lorvotuzumab can be used to synthesize antibody-drug conjugate (Lorvotuzumab mertansine). | |||
T77911 | Cantuzumab | ||
Cantuzumab, a monoclonal antibody, binds to the CanAg antigen and is commonly conjugated with various cytotoxic agents to form antibody-drug conjugates (ADCs), including Cantuzumab mertansine and Cantuzumab ravtansine [1... | |||
T18678 | SC-VC-PAB-DM1 | Others | |
SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity. | |||
T17793 | DBCO-PEG4-Ahx-DM1 | Others | |
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific deliv... | |||
T17832 | DM1-PEG4-DBCO | Others | |
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to m... | |||
T80217 | BT1718 | MMP | |
BT1718 is a bicyclic peptide conjugate that targets MT1-MMP, a protease overexpressed in various advanced solid tumors such as triple-negative breast cancer (TNBC) and non-small cell lung cancer [1] [2]. By exploiting MT... |